Switzerland - Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry
Since 2014, Switzerland Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry grew 3.8% year on year. In 2019, the country was number 5 comparing other countries in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry with $5,040,677,150.71 Million PPP. Switzerland is overtaken by Germany, which was ranked number 4 with $6,508,976,256.92 Million PPP and is followed by Belgium at $3,043,879,424.39 Million PPP. United States topped the ranking with $70,565,318,932.39 Million PPP in 2019, that is +3.3% compared to 2018. Iceland recorded the best 5 years average growth at +43.9% per year, while Lithuania recorded the worst performance at -42.6% per year.
Loading...
Date | Million US Dollars PPP |
---|---|
2019 | 5,040,677,150.71 |
2018 | 4,884,638,353.99 |
2017 | 4,703,697,087.01 |
2016 | 4,610,878,582.44 |
2015 | 4,481,909,042.17 |
How does Switzerland rank in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry?
# | 69 Countries | Million US Dollars PPP | Last | YoY | 5‑years CAGR | ||
---|---|---|---|---|---|---|---|
1 |
#1
United States
|
70,565,318,932.39 | 2019 | +3.3 % | +4.5 % | View data | |
2 |
#2
China
|
13,956,388,273.35 | 2019 | +4.5 % | +6.1 % | View data | |
4 |
#4
Germany
|
6,508,976,256.92 | 2019 | +2.7 % | +4.4 % | View data | |
5 |
#5
Switzerland
|
5,040,677,150.71 | 2019 | +3.2 % | +3.8 % | View data | |
6 |
#6
Belgium
|
3,043,879,424.39 | 2019 | +4.4 % | +9.3 % | View data |